Propiverine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 29, 2026🚩 Report this page

Propiverine

Drugs For Urinary Frequency and Incontinence

GB MHRA

Drug class: Drugs For Urinary Frequency and Incontinence
Availability: See label
Markets covered: 1
Products on record: 22

G04BDDrugs For Urinary Frequency and Incontinence

Overview

Propiverine is an active pharmaceutical ingredient in the Drugs For Urinary Frequency and Incontinence group (G04BD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	22	May 29, 2026

GBUnited Kingdom· MHRA

22 products

Uses

GBOfficial regulatory label· revised April 10, 2026[1]

Symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder.

How to take

Sources & citations

[1]MHRA (UK) · PL248370127 · revised April 10, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised April 10, 2026[1]

Within each system organ class, the undesirable effects are ranked under heading of frequency using the following convention: Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000) Not known (cannot be estimated from the available data).
All undesirable effects are transient and recede after a dose reduction or termination of the therapy after maximum 1-4 days. System organ class (Disorders according to MedDRA) Adverse reactions Immune system disorders Rare: - hypersensitivity Psychiatric disorders Very rare - restlessness, confusion Not known - hallucination Nervous system disorders Common - headache Uncommon - tremor, dizziness, dysgeusia Not known - speech disorder Eye disorders Common - accommodation disorder, visual impairment Cardiac disorders Rare - tachycardia Very rare - palpitation Vascular disorders Uncommon - decreased blood pressure with drowsiness, flushing Gastrointestinal disorders Very common - dry mouth Common - constipation, abdominal pain, dyspepsia Uncommon - nausea/vomiting Skin and subcutaneous tissue disorders Uncommon - pruritus Rare - rash Renal and urinary disorders Uncommon - urinary retention, bladder and urethral symptoms General disorders and administration site conditions Common - fatigue .
During long-term therapy hepatic enzymes should be monitored, because reversible changes of liver enzymes might occur in rare cases. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised April 10, 2026[1]

2). Symptoms of the following diseases may be aggravated following administration of the drug: - severe congestive heart failure (NYHA IV) - prostatic enlargement - hiatus hernia with reflux oesophagitis - cardiac arrhythmia - tachycardia.
Propiverine, like other anticholinergics, induces mydriasis. Therefore, the risk to induce acute angle-closure glaucoma in individuals predisposed with narrow angles of the anterior chamber may be increased. Drugs of this class, including propiverine, have been reported to induce or precipitate acute angle-closure glaucoma.
g. urinary tract infections, malignancy) should be ruled out prior to treatment. This product contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption should not take this medication.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations